Biovica update: US progress - Redeye

Redeye updates our Biovica outlook after reporting the full 2022/23. Biovica has secured two PPO contracts and the company is in progress to contract individual Hospitals and cancer centers. We make a smaller revision and the main value driver is additional contracts and the ability to to activate DiviTum use in Biovica’s expanding US network.. Our updated Base Case reflects a Base Case is SEK 28 ( 29) with a Bull of SEK 60 (50) and a Bear case of SEK 5 ( 7).

Länk till analysen i sin helhet: https://www.redeye.se/research/917945/biovica-update-us-progress?utm_source=finwire&utm_medium=RSS